Date: 2013-10-11
Type of information: Licensing agreement
Compound: antibody-drug conjugate (ADC) technology
Company: ImmunoGen (USA) Novartis (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen\'s highly potent cancer-cell killing agents specifically to tumor cells.
Disease:
Details:
The most advanced compound with ImmunoGen\'s ADC technology is Roche’s Kadcyla®, which is marketed in the US by Genentech and also gaining approvals internationally. ImmunoGen has four wholly owned clinical-stage product candidates, with additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi (SAR3419).
Financial terms: This is the second license to be taken by Novartis under a 2010 agreement between the companies. For each license, ImmunoGen receives an upfront payment and is entitled to receive milestone payments potentially totaling approximately $200 million plus royalties on the sales of any resulting products. Novartis is responsible for the development, manufacturing and marketing of any products resulting from the license.
Latest news: